ArticleAmerican journal of translational research2017
Loss of PRRX1 induces epithelial-mesenchymal transition and cancer stem cell-like properties in A549 cells.
Article in American journal of translational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 12 citations in OpenAlex.
- Epithelial-mesenchymal transition and its transcription factors.Bioscience reports · 2022Review
- PRRX1 promotes malignant properties in human osteosarcoma.Translational oncology · 2021Article
- Predicted regulatory SNPs reveal potential drug targets and novel companion diagnostics in psoriasis.Journal of translational autoimmunity · 2021Article
- The Regulatory Role of PRRX1 in Cancer Epithelial-Mesenchymal Transition.OncoTargets and therapy · 2021Review
- COL6A3 expression in adipose tissue cells is associated with levels of the homeobox transcription factor PRRX1.Scientific reports · 2020Article
- Paired‑related homeobox 1 overexpression promotes multidrug resistance via PTEN/PI3K/AKT signaling in MCF‑7 breast cancer cells.Molecular medicine reports · 2020Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial-mesenchymal transition (EMT) plays crucial role in tumor metastasis and patient prognosis. Previous studies indicated that paired-related homeobox 1 (PRRX1), a newly identified EMT inducer, plays opposing roles in different tumor cell types. However, the function of PRRX1 in lung cancer has not been elucidated. In the present study, we observed that the expression level of PRRX1 was high in A549 cells, and a loss of PRRX1 induced EMT by regulating the EMT markers N-cadherin, E-cadherin and vimentin in A549 cells. This loss also distinctly affected cell morphology, migration and invasion. Moreover, a loss of PRRX1 increased the expression levels of cancer stem cell (CSC) markers and promoted the proliferation of these cells. These findings demonstrated that PRRX1 inhibits EMT and induces CSC-like properties in A549 cells.
Indexed as
Identifiers
28469771PMC5411914W3022013336What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.